Stage 0 Breast Cancer: What DCIS Means and Why Early Detection Matters

Stage 0 breast cancer can be a confusing term. The word cancer can feel frightening, while Stage 0 may sound as though it is not serious or does not really count.

A recent Hackensack Meridian Health article explores ductal carcinoma in situ (DCIS), how it is commonly detected and treated, and one patient’s experience receiving the diagnosis. Bram Goldstein, Ph.D., President and Senior Clinical Fellow of the Women’s Cancer Research Foundation, provides additional clinical context.

A Clinical Perspective of Stage 0 Breast Cancer from Bram Goldstein, Ph.D.

Stage 0 breast cancer, or ductal carcinoma in situ (DCIS), is the earliest form of breast cancer, and accounts for about 20 percent to 25 percent of new breast cancer diagnoses annually. The disease is noninvasive, meaning the abnormal cells are only in the lining of the breast’s milk ducts and haven’t spread to the surrounding tissue. Typically, the disease presents as tiny calcifications on a mammogram.

When stage 0 breast cancer is caught at this stage, it’s highly treatable, with a five-year survival rate of 99%.

Treatment for Stage 0 breast cancer may include a combination of surgery, radiation therapy, and hormone therapy. A lumpectomy removes just the cancerous area and is followed by radiation to lower the chance of the cancer returning. A mastectomy removes the whole breast (or both) and usually doesn’t need radiation.

Some patients also take an anti-estrogen pill daily for five years to reduce the risk of recurrence. Since DCIS is noninvasive, chemotherapy isn’t usually indicated. Ultimately, the key is early detection with an annual mammogram.

Why This Matters

Finding breast changes early can make a meaningful difference, but breast cancer screening and treatment are not one-size-fits-all. Recommendations about when to begin mammograms and how often to have them vary among medical organizations. Individual recommendations may also be influenced by age, personal and family history, breast density, previous findings, and other risk factors.

Anyone with questions about when to begin screening, how frequently to be screened, or whether additional imaging may be appropriate should speak with a qualified healthcare professional.

DCIS also remains an important area of breast cancer research. Researchers are studying how to better identify which cases are most likely to become invasive and whether some people with low-risk DCIS may be candidates for careful monitoring rather than immediate surgery. The goal is more individualized care—helping each person receive treatment appropriate to their specific diagnosis while avoiding treatment that may not be necessary.

Research such as the National Cancer Institute’s COMET clinical trial is helping investigators compare active monitoring with surgery for certain cases of low-risk DCIS. Questions like these matter because detecting cancer earlier is only part of the challenge. Researchers must also continue learning how different diagnoses behave and how each one can be treated most appropriately.

Read the original article: Stage 0 Breast Cancer Explained — Hackensack Meridian Health

Medical note: This article is intended for educational purposes only and does not provide medical advice, diagnosis, or individualized screening or treatment recommendations. Please consult a qualified healthcare professional about personal health concerns.